Idiopathic Pulmonary Fibrosis | Unmet Need | US/EU5 | 2021

Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung function, and prolong survival are sorely needed. The diverse IPF pipeline comprises novel classes including CTGF inhibitors, ROCK2 inhibitors, and agents targeting recombinant human pentraxin-2. In this report, we assess the clinical and commercial opportunities remaining in the IPF space through a comprehensive analysis of surveyed pulmonologists’ treatment drivers and goals, and their perception of the performance of key current therapies against these goals.


  • What are the key treatment drivers and goals for IPF?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies such as Esbriet and Ofev perform on key treatment drivers and goals for IPF?
  • What are the key opportunities for drug development in IPF? Where do surveyed pulmonologists perceive the largest gaps in the treatment of IPF patients?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new IPF drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European pulmonologists fielded in January 2021

Key companies: Roche, Boehringer Ingelheim, FibroGen, Promedior / Roche

Key drugs: Esbriet, Ofev, prednisone

Login to access report